Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC

Key Points

• UBS AM reduced its stake in Alnylam Pharmaceuticals by 65.7% in the first quarter, owning approximately 0.56% of the company valued at $198.8 million after selling over 1.4 million shares.
• Insider sales at Alnylam Pharmaceuticals included Director Colleen F. Reitan selling 18,000 shares for $8.4 million, resulting in a 95.87% decrease in her position.
• Alnylam Pharmaceuticals recently reported earnings of $0.32 EPS, exceeding expectations significantly, with revenues of $773.7 million, marking a 17.3% increase year-over-year.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 65.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 736,111 shares of the biopharmaceutical company's stock after selling 1,409,487 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 0.56% of Alnylam Pharmaceuticals worth $198,765,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. SVB Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $27,000. Whipplewood Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares in the last quarter. Park Square Financial Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $28,000. Finally, Washington Trust Advisors Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 53.5% during the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after acquiring an additional 61 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Insider Buying and Selling

In other news, Director Michael W. Bonney sold 11,250 shares of the company's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the completion of the sale, the director directly owned 16,804 shares in the company, valued at $7,561,800. This represents a 40.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Colleen F. Reitan sold 18,000 shares of the company's stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total value of $8,416,800.00. Following the sale, the director owned 775 shares of the company's stock, valued at approximately $362,390. The trade was a 95.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 75,594 shares of company stock worth $33,968,256 in the last three months. 1.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ALNY shares. JPMorgan Chase & Co. boosted their price target on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Chardan Capital upped their target price on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a "buy" rating in a research note on Friday, August 1st. HC Wainwright reaffirmed a "buy" rating and issued a $570.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, September 2nd. Barclays upped their target price on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Finally, Jefferies Financial Group upped their target price on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research note on Monday, July 7th. Twenty-three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $421.28.

Alnylam Pharmaceuticals Trading Down 0.6%

ALNY traded down $2.69 during trading on Friday, hitting $465.89. The company's stock had a trading volume of 630,774 shares, compared to its average volume of 1,109,281. The firm's 50 day moving average price is $401.46 and its 200-day moving average price is $317.91. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The stock has a market cap of $61.07 billion, a PE ratio of -188.62 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.Alnylam Pharmaceuticals's revenue was up 17.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.